Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Delta Air Lines, Inc. (DAL) vs McKesson Corporation (MCK) Price & Performance

Delta Air Lines, Inc.Trade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Delta Air Lines, Inc. vs McKesson Corporation — how do they compare? Delta Air Lines, Inc. trades at $90.5 (market cap $58.67B), while McKesson Corporation trades at $901.77 (market cap $102.58B). The key difference: McKesson Corporation is the larger of the two by market cap, and Delta Air Lines, Inc. pays the higher dividend (0.87%). Which is the better fit depends on your goals.

DALMCK
Market Cap
$58.67B$102.58B
Sector
IndustrialsHealth
52-Week High
$93.66$995.69
52-Week Low
$53.50$659.01
Enterprise Value
$73.99B$109.12B
Dividend Yield
0.87%0.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Delta Air Lines, Inc.

Delta Air Lines (DAL) trades at $91.34, down 0.7% today, amid a bullish technical trend and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q3 2026 EPS expected at $2.19. Valuation metrics like a P/E of 15.15 and P/S of 0.88 suggest potential undervaluation, while cash flow trends improved to a net positive $1.08B in 2025. Recent news highlights insider sales but also strong Q2 results and industry tailwinds.

Outlook remains positive with an 81.82% analyst buy rating and consensus price target of $108.27, implying ~18% upside. Key risks include fuel cost volatility and competitive pressures, but DAL's premium travel demand and loyalty program strength support growth. Investors should weigh solid fundamentals against macroeconomic sensitivities.

McKesson Corporation

McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.

Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Delta Air Lines, Inc.

Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.

Read more on DAL

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK